Could a Low-Dose immune drug stop recurrent miscarriages?
NCT ID NCT03970954
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early trial tested whether low doses of interleukin-2 (IL-2) could boost regulatory T cells in women who had at least five unexplained miscarriages. The goal was to see if this immune-calming approach could eventually prevent the body from rejecting a pregnancy. Only 18 women took part, and the study measured changes in immune cells rather than actual pregnancy success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low-dose interleukin-2 (IL-2)
- What this could lead to
- If it works, this could lead to a treatment that prevents miscarriages by calming the immune system.
- What could go wrong
- This is a very small, early-phase trial with only 18 participants. It only measured immune cell changes, not pregnancy outcomes, so it may not lead to a proven therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MISCARRIAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bornes
Paris, Hopital Tenon, 75020, France
-
Kayem
Paris, Hopital Trousseau, 75012, France
-
Mekinian
Paris, Hopital Saint Antoine, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.